Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Declines By 69.2%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 6,999 shares, a decline of 69.2% from the April 15th total of 22,704 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 33,057 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

Several research firms have recently issued reports on BOLT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Friday, March 13th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $41.00.

Institutional Trading of Bolt Biotherapeutics

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after acquiring an additional 22,200 shares during the period. T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth approximately $208,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth approximately $112,000. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics in the third quarter worth approximately $89,000. Finally, Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics in the third quarter worth approximately $85,000. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Price Performance

BOLT opened at $4.78 on Friday. The stock has a 50-day moving average price of $4.61 and a 200-day moving average price of $5.12. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.59. The firm has a market cap of $9.18 million, a PE ratio of -0.29 and a beta of 1.10. Bolt Biotherapeutics has a 1 year low of $3.91 and a 1 year high of $9.25.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Sell-side analysts predict that Bolt Biotherapeutics will post -9.54 earnings per share for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.